

HSL

# CURRENT MEDICAL RESEARCH

---

## and Opinion

Volume 14 Number 4 1998

ISSN 0300-7995

SUBJECT	CONTENTS	page
Erectile dysfunction; NO; Nitroglycerin; Sildenafil; cGMP	Opportunities for the Treatment of Erectile Dysfunction by Modulation of the NO Axis – Alternatives to Sildenafil Citrate. <i>Christian de Mey</i>	187
Buccal prochlorperazine; Oral prochlorperazine; Dizziness; Nausea; Vomiting	Comparison of Buccal and Oral Prochlorperazine in the Treatment of Dizziness Associated with Nausea and/or Vomiting. <i>C. M. Bond</i>	203
Psoriasis; Vitamin D <sub>3</sub> analogues; Tacalcitol	Current Experience with Tacalcitol Ointment in the Treatment of Psoriasis. <i>H. Gollnick and T. Menke</i>	213
Conscious sedation; Analgesia; Clinical investigation	Is Chloral Hydrate/Hydroxyzine a Good Option for Paediatric Dental Outpatient Sedation? <i>Verónica Avalos-Arenas, Diana Moyao-García, Alejandro A. Nava-Ocampo, Rocío E. Zayas-Carranza and Rodolfo Frago-Ríos</i>	219
Ispaghula husk; Lactulose; Laxatives; Constipation	A Multi-centre, General Practice Comparison of Ispaghula Husk with Lactulose and Other Laxatives in the Treatment of Simple Constipation. <i>Peter W. Dettmar and John Sykes</i>	227
Chronic hepatitis C; Efficacy; Human leukocyte interferon- $\alpha$ ; Recombinant interferon- $\alpha$ ; Lymphoblastoid interferon- $\alpha$	Comparative Responses to Three Different Types of Interferon- $\alpha$ in Patients with Chronic Hepatitis C. <i>G. Montalto, M. Soresi, A. Carroccio, G. Anastasi, P. Campagna, F. Vasile, L. Di Prima, A. Cartabellotta, L. Giannitrapani and M. Fulco</i>	235
RW94; Body weight; Obesity	A Double-blind, Placebo-controlled Evaluation of the Effects of RW94 on the Body Weight of Both Overweight and Obese Healthy Volunteers. <i>A. R. Williams</i>	243

HEALTH SCIENCES LIBRARY  
University of Wisconsin

JAN 14 1999

1305 Linden Drive

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

## General Information

---

*Current Medical Research and Opinion* is an international journal devoted to publishing, in the English language, the results of original research and clinical investigation of pharmaceutical preparations used in medical treatment, and other topics of general medico-scientific interest. Studies carried out anywhere in the world will be considered, the basic criterion for acceptance being the scientific and medical standard of the work described. Manuscripts submitted for publication are scrutinised by independent expert assessors and, once accepted, will be published promptly.

*Current Medical Research and Opinion* is published periodically according to demand. It is distributed to medical schools, medical libraries, selected hospitals and research institutions throughout the world, and by subscription to any other interested individuals or organisations.

*Current Medical Research and Opinion* is listed in *Current Contents/Clinical Practice*, and indexed in *EMBASE/Excerpta Medica* and other major data-retrieval systems and other abstracting services. It is also available in microform from University Microfilms International.

## Disclaimer

Views and factual claims expressed in individual contributions are personal to the respective contributors and are not necessarily endorsed by the editor, advisers, publishers or distributors of this journal.

## Subscription Information

Subscriptions, payable in advance, are on a four-issue volume basis and not annually. Rates per volume, surface mail included, are: UK and EC countries – £50; USA and all other countries – £60 (US\$ 103). Rates for air mail postage and bulk subscriptions for single issues are available on request.

## Missing Issues

Missing copies will be replaced free of charge only if notified *no later than two months* after publication of the next issue in the volume sequence; all other replacement copies must be paid for at the single issue rate.

## Notes for Contributors

See inside back over.

## Copyright

© LibraPharm Limited. All rights reserved. None of the contents of this publication may be reproduced in whole or in part, translated, stored in a retrieval system, or transmitted or distributed in any form or by any means (electronic, mechanical, photocopy, recording or otherwise) without the prior written permission of the Publishers.

## Editorial Advisers

Prof. G. E. Ehrlich (Chairman) (Philadelphia, USA); Prof. A. Atkinson (Salisbury, UK); Prof. N. Bellamy (Hamilton, Ontario, Canada); Prof. G. R. D. Catto (Aberdeen, UK); Dr W. M. Chong (Kuala Lumpur, Malaysia); Dr P. Dawes (Wilmslow, UK); Prof. B. M. Hegde (Mangalore, India); Prof. R. Marks (Cardiff, UK); Prof. E. Szabadi (Nottingham, UK); Prof. W. Watson Buchanan (Hamilton, Ontario, Canada); Dr D. Whynes (Nottingham, UK); Dr K. C. Wong (Kuala Lumpur, Malaysia).

Managing Editor: P. L. Clarke, MA, PhD

Publishers: LibraPharm Limited, 3B Thames Court, Goring-on-Thames, READING, Berkshire RG8 9AQ, UK.  
Tel: +44 (0)1491 875252; fax: +44 (0)1491 875200; email: journals@libraphar.co.uk

Listed in *Current Contents/Clinical Practice* and indexed in *EMBASE/Excerpta Medica*

# Opportunities for the Treatment of Erectile Dysfunction by Modulation of the NO Axis – Alternatives to Sildenafil Citrate

Christian de Mey

Applied Clinical Pharmacology Services, Philippsring 11, D-55252 Mainz-Kastel, Germany

Key words: *Erectile dysfunction – NO – Nitroglycerin – Sildenafil – cGMP*

HEALTH SCIENCES LIBRARY  
University of Wisconsin

JAN 14 1999

1305 Linden Drive

## Summary

*Erectile function in man depends upon a complex interaction of psychogenic, neurologic, hormonal and vascular factors, and therefore the management of erectile dysfunction (ED) reflects this complexity of control. Therapeutic options include psychological and non-pharmacological approaches as well as drug treatments. The effectiveness of the type-5 cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra®) confirms the pivotal role of the NO-cGMP axis in promoting and maintaining erection. Although widely acclaimed, sildenafil leaves many questions unanswered, especially regarding its susceptibility to pharmacokinetic drug interactions, and its safety in patients with ischaemic heart disease and those taking nitrates. In view of the epidemiological link between erectile dysfunction and cardiovascular disease in the elderly, this limitation might have much broader implications. The presently available scientific documentation, although less extensive, indicates that NO donors, such as topically applied nitroglycerin (GTN; for example, 1–2 puffs of an ordinary GTN spray applied to the shaft of the penis), might be a reasonable alternative. Further larger-scale research on the efficacy and tolerability of topical GTN is needed to establish its full therapeutic potential in the treatment of erectile dysfunction.*

## Introduction

Penile erection is the major functional expression of sexual arousal in man and therefore plays a key role in human sexual behaviour. Historically, the term 'impotence' has been used for a wide range of male sexual dysfunctions, including low sexual desire, retarded ejaculation, and difficulties in achieving and sustaining erections<sup>1</sup>. Owing to pejorative connotations and lack of specificity it has now mostly been replaced by 'erectile dysfunction' or 'erectile disorder' (ED) to signify a persistent or recurrent inability to attain and/or maintain an adequate erection to permit satisfactory

sexual intercourse (highlighting penile erection as a part of the multifaceted process of male sexual function)<sup>1</sup>. In 1992, the NIH Consensus Statement on Impotence estimated 10–20 million U.S. males to be affected, with a 5% prevalence at the age of 40 increasing to 15–25% at the age of 65 and older<sup>2</sup>; later surveys indicate an overall prevalence of 52% of men aged 40–70 years in the Massachusetts Male Aging Study<sup>3</sup>.

Undoubtedly, ED is not a mere inconvenience, but the source of important distress and social isolation<sup>4</sup> as it may be perceived by the ego-threatened male as a vital 'insult to his manhood'<sup>5</sup> often experienced with both shame and guilt<sup>6</sup>.



Until recently, the lack of simple definitions, appropriate wording and convenient therapeutic options may have discouraged both health-care providers and patients to consider ED as a legitimate medical issue rather than as an embarrassing psycho-social oddity: only a few patients sought medical help, which then often consisted of lengthy psychological counselling, complex medical devices, painful local intracavernous injections or surgery, etc.

The overwhelming – albeit not unequivocal – public acclaim of the introduction of sildenafil citrate (Viagra®), the first peroral treatment of ED with an adequately proven efficacy claim, redefines ED as a lifestyle rather than as a (conventional) medical issue: very many males appear to be unsatisfied with their sexual (erectile) performance – although they would probably not consider themselves ‘impotent’ – and are eager to seek pharmacological help for it, provided it can be achieved conveniently.

However, sildenafil citrate has important drawbacks. Safety concerns exclude an important fraction of the affected population – those with cardiovascular diseases and those taking nitrates, in particular. Against this background of well-documented experience with sildenafil citrate, which confirms the NO–cGMP hypothesis, it is appropriate to evaluate further options for the management of erectile dysfunction.

## Physiology

Anatomically, the erectile system of the human male penis consists of the corpus cavernosum (two chambers adjacent to the urethra which runs on the underside of the corpora) and the corpus spongiosum (composed of large venous sinuses which contain little blood when the penis is flaccid,

engorged with blood)<sup>7</sup>.

Penile erection is a vascular event initiated by neuronal action and maintained by a critical interplay between vascular and neurological processes. Psychogenic stimulation (perception, desire, etc) and/or tactile (reflexogenic) stimulation initiate the process. Centrally mediated erection impulses reach the penis via the thoracolumbar sympathetic outflow and hypogastric plexus. The afferent fibres in the pudendal nerve carry the tactile impulses to the erection centre in the sacral cord, which returns efferent signals through parasympathetic nerve fibres. Full erection requires input from both central and reflex pathways.

In the flaccid penis, the blood pressure in the cavernosal sinuses is near to venous pressure and the smooth muscles of the penile arteries and the trabeculae of the corpus cavernosum are contracted in order to maximise the impedance against arterial inflow; this tone is kept by the excitatory adrenergic innervation although spontaneous myogenic activity may play an ancillary role<sup>8</sup>. Relaxation of the corpus cavernosum smooth muscle is the pivotal physiological event responsible for erection. Increased inflow fills the cavernous lacunar spaces increasing the pressure within the spaces so that the penis becomes erect<sup>9</sup>.

## Pharmacology

Although confounded by methodological constraints and species heterogeneity, experiments *in vitro* and *in vivo* conducted in man, animals and cultured cells, allow definition of several working hypotheses to identify suitable approaches to therapeutic intervention in ED.

Tumescence depends on the changing balance between neuronal and humoral messengers that affect myosin



tone: filling of the sinusoidal spaces with blood due to smooth muscle cell relaxation results from an increased efferent parasympathetic tone (and probably simultaneous withdrawal of the efferent adrenergic drive), with nitric oxide (NO) as the main proerectile neurotransmitter and noradrenaline as the major antierecile agent<sup>10-12</sup>.

### Central Nervous Control

Centrally, apomorphine, a D<sub>1</sub>- and D<sub>2</sub>-dopaminergic agonist, facilitates erection through stimulation of the D<sub>1</sub>-receptors in the hypothalamic medial preoptic area, while higher doses inhibit erection by stimulation of D<sub>2</sub>-receptors<sup>13,14</sup>. *Oxytocinergic* nerves appear to enhance erection both directly and by modulating limbic dopaminergic activity<sup>15</sup>. *Serotonin* modulates spinal reflex activity in the spinal cord, with 5-HT<sub>2</sub>-receptor stimulation inhibiting erection and facilitating ejaculation, while 5-HT<sub>1c</sub>-agonists (such as trazodone<sup>16</sup>) augment erectile responses by amplifying the efferent parasympathetic drive. *NO* synthase (nNOS or Type I) has been co-localised with various central nervous neurotransmitters in selective parts of the brain and spinal cord, including the paraventricular nucleus; although predominantly a peripheral modulator (see below), central nervous NO might act as a long-term synaptic modulator following its release from presynaptic neurones<sup>17</sup>.

### Peripheral Nervous Modulation

Penile erection relies on stimulation of the pelvic (nervi erigentes) and cavernous nerves. The latter originate from the pelvic plexus, which is modulated by parasympathetic (pelvic nerve), sympathetic (hypogastric nerve) and somatic (pudendal

Although cholinergic nerves have been identified in the penile effector system, muscarinergic blockade does not appear to alter nerve-evoked penile smooth muscle relaxation<sup>18</sup>; acetylcholine has dual, mainly indirect, effects by stimulating endothelial NO release and by releasing noradrenaline via stimulation of prejunctional muscarinic receptors.

Increased cavernosal smooth muscle tone and penile flaccidity is controlled by postjunctional  $\alpha_1$ -adrenoceptors and increased  $\alpha$ -adrenoceptor sensitivity has been suggested to play a role in ED<sup>19</sup>.

Physiologically the main peripheral neurotransmission pathway to induce penile erection seems to be non-cholinergic, non-adrenergic and mediated by the EDRF-analogue NO<sup>20</sup>. NO is synthesised endogenously during the conversion of L-arginine to L-citrulline as catalysed by NO synthase (NOS). NO activates guanylate cyclase which then catalyses the formation of guanosine 3',5'-cyclic monophosphate (cGMP) from guanosine 5'-triphosphate. As a secondary messenger, cGMP inhibits myosin phosphorylation and reduces intracellular calcium concentrations via activation of cGMP kinase<sup>21</sup>. NOS has been localised in the penile effector system in neurones (nNOS, Type I), endothelium (eNOS, Type III) and smooth muscle (inducible iNOS, Type II)<sup>12</sup>. Experimentally, penile NOS was found to be reduced in several conditions associated with ED (such as senescence, castration, diabetes, adrenalectomy, hypophysectomy and androgen receptor blockade), while substitution of the respective hormones prevented ED and loss of NOS<sup>22</sup>. NO-mediated relaxation is impaired by excess prolactin<sup>23</sup>. Neurogenic penile smooth muscle cell relaxation can be blocked by inhibitors of NO biosynthesis and by substances that reduce cGMP or bind directly to NO, while NO-donors, such as GTN and

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.